Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diamyd in newly diagnosed Type 1 Diabetes
NCT00751842Phase 3Terminated
- Sponsor
- Diamyd Medical
- Start
- Sep 2008
- Primary completion
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes, Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Diamyd in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Diamyd Medical. Primary endpoint: Meal Stimulated C-peptide (area under the curve) at 15 months. Started Sep 2008; status: terminated.
02
Drugs
Diamyd
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00751842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751842.